Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation

Yang Liu, MD, Elise A. Chong, MD, Sigrid Berg, MD, Abass Alavi, MD, Rodolfo Perini, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Anthony Mato, MDMSCE, Stephen J. Schuster, MD

Blood (2014) 124 (21): 5471.

https://doi.org/10.1182/blood.V124.21.5471.5471

Published: 2014

Journal Articles

Dual Time Point FDG-PET/CT Imaging Can Distinguish Between Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

Elise A. Chong, MD, Drew Torigian, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2014) 124 (21): 1613.

https://doi.org/10.1182/blood.V124.21.1613.1613

Published: 2014

Journal Articles

Maximum Standard Uptake Value (SUVmax) on FDG-PET Imaging Predicts Time to First Treatment in Patients with Low Grade Follicular Lymphoma,

Jakub Svoboda, MD, Elise A. Chong, BA, Emeline R Chong, Sunita D. Nasta, MD, Drew Torigian, MD, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2011) 118 (21): 4204.

https://doi.org/10.1182/blood.V118.21.4204.4204

Published: 2011

Journal Articles

Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.

Elise A. Chong, BA, Drew A. Torigian, MD, MA, Abass Alavi, MD, Jakub Svoboda, MD, Anthony R Mato, MD, Sunita Dwvedy Nasta, MD, Lisa H. Downs, CRNP, Stephen J. Schuster, MD

Blood (2009) 114 (22): 1402.

https://doi.org/10.1182/blood.V114.22.1402.1402

Published: 2009

Journal Articles

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Ivan Maillard, MDPhD, Rebecca L. Elstrom, MD, Rakesh Kumar, MD, Murat F. Bozkurt, MD, Srikant Sankaran, MD, Liang Guan, MD, Hongming Zhuang, MDPhD, David Herman, Lisa Downs, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2004) 104 (11): 4565.

https://doi.org/10.1182/blood.V104.11.4565.4565

Published: 2004

NARROW

Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation

Dual Time Point FDG-PET/CT Imaging Can Distinguish Between Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

Maximum Standard Uptake Value (SUVmax) on FDG-PET Imaging Predicts Time to First Treatment in Patients with Low Grade Follicular Lymphoma,

Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation

Dual Time Point FDG-PET/CT Imaging Can Distinguish Between Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

Maximum Standard Uptake Value (SUVmax) on FDG-PET Imaging Predicts Time to First Treatment in Patients with Low Grade Follicular Lymphoma,

Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only